High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis.

Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, Lund A, Bokarewa M. Semin Arthritis Rheum. 2012 Apr;41(5):652-7.